Pharos MT Limited (production of finished medicinal product, primary and secondary packaging, batch control, batch release)
UkraineAll drugs from this manufacturer
-
The drug is prescribed for the treatment of the chronic phase of chronic myeloid leukemia (CML) in adults and children. It is also used in adult and pediatric patients in cases of resistance or intolerance to prior therapy (e.g., imatinib).
Dosage form: capsules, hard
Active substance Dosage nilotinib 50 mg ATC: L01EA03
-
The drug is prescribed for the treatment of chronic myeloid leukemia (Ph+ CML) in adults and children. It is used both at the initial diagnosis of the chronic phase of the disease and in the chronic or accelerated phases, if previous therapy (e.g., imatinib) was ineffective or unsuitable for the patient.
Dosage form: capsules, hard
Active substance Dosage nilotinib 150 mg ATC: L01EA03
-
The drug is prescribed for the treatment of the chronic phase of chronic myeloid leukemia (CML) in adults and children. It is also used in adult and pediatric patients in cases of resistance or intolerance to prior therapy (including imatinib).
Dosage form: capsules, hard
Active substance Dosage nilotinib 200 mg ATC: L01EA03